Published February 28, 2026 | Version v1
Journal article Open

MOLECULAR HEMATOLOGY OF CHRONIC MYELOID LEUKEMIA: RECENT ADVANCES IN PATHOGENESIS, DIAGNOSIS AND TARGETED THERAPIES – AN UPDATED REVIEW

Authors/Creators

Description

Background: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm driven by the BCR::ABL1 fusion oncogene, resulting from the reciprocal translocation t(9;22)(q34;q11.2). The development of tyrosine kinase inhibitors (TKIs) targeting BCR::ABL1 has revolutionized CML therapy, transforming a once-fatal disease into a manageable chronic condition with near-normal life expectancy. Objective: This comprehensive review synthesizes recent advances in the molecular pathogenesis, diagnostic approaches, therapeutic strategies, and emerging challenges in CML management, with a focus on developments from 2020-2025. Methods: We conducted a systematic review of peer-reviewed literature from PubMed, Scopus, and Web of Science databases, emphasizing clinical trials, consensus guidelines, and molecular studies published between 2000-2025. Results: Six TKIs are currently approved for CML treatment: imatinib (first-generation), dasatinib, nilotinib, bosutinib (second-generation), and ponatinib and asciminib (third-generation). Frontline therapy achieves 10-year overall survival rates of 82-87% and relative survival of 90-95%. Treatment-free remission (TFR) is achievable in 40-60% of patients with sustained deep molecular response (DMR) for ≥2 years, with TFR rates reaching 80-85% after ≥5 years of DMR. Resistance mechanisms include BCR::ABL1 kinase domain mutations (notably T315I), clonal evolution, and BCR::ABL1-independent pathways. The T315I "gatekeeper" mutation confers resistance to all first- and second-generation TKIs but is sensitive to ponatinib and asciminib. Cardiovascular toxicity remains a significant concern with second- and third-generation TKIs, particularly nilotinib and ponatinib. Emerging third-generation TKIs (olverembatinib, TGRX-678, TERN-701, ELVN-001) show promising efficacy in resistant disease. Conclusion: The molecular era has established precision medicine for CML, with ongoing research focused on overcoming resistance, increasing TFR rates, managing long-term toxicities, and ensuring global access to effective therapies.

Files

5 WJAPS 369.pdf

Files (946.1 kB)

Name Size Download all
md5:f8f3ed472493c85310c12f443d5d610c
946.1 kB Preview Download

Additional details

Identifiers

ISSN
3049-3013

Related works

Is referenced by
Journal article: 3049-3013 (ISSN)

References

  • Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin., 2022; 72(1): 7-33.
  • Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol, 2022; 97(9): 1236-56.
  • Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer, 2012; 118(12): 3123-7.
  • Sasaki K, Haddad FG, Short NJ, et al. Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer, 2023; 129(23): 3805-14.
  • Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst., 2011; 103(7): 553-61.
  • Kantarjian H, Jabbour E, Cortes J. Chronic Myeloid Leukemia. In: Loscalzo J, Fauci A, Kasper D, et al., eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education, 2022.
  • Leukemia EiCM. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013; 121(22): 4439-42.
  • Hamid GA, Clinical hematology [2013]. https://doi.org/10.13140/RG.2.1.1477.1683
  • Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature, 1973; 243(5405): 290-3.
  • Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell., 1984; 36(1): 93-9.
  • Hamid GA (2015) Treatment Development of Chronic Myeloid Leukemia.J Develop Drugs, 4: e144. doi:10.4172/2329-6631.1000e144
  • Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med., 2006; 355(23): 2408-17.
  • Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med., 2017; 376(10): 917-27.
  • Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia, 2016; 30(1): 48-56.
  • Abdul Hamid G (ed.) (2019) Advances in Hematologic Malignancies. IntechOpen. Available at: http://dx.doi.org/10.5772/intechopen.77785.
  • Soverini S, Mancini M, Bavaro L, et al. Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy. Mol Cancer, 2018; 17(1): 49.
  • O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell, 2009; 16(5): 401-12.
  • Moslehi JJ, Deininger M. Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. J Clin Oncol, 2015; 33(35): 4210-8.
  • Mahon FX. Treatment-free remission in CML: who, how, and why? Hematology Am Soc Hematol Educ Program, 2017; 2017(1): 102-9.
  • Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program, 2019; 2019(1): 433-42.
  • Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood, 2000; 96(10): 3343-56.
  • O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer, 2012; 12(8): 513-26.
  • Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood, 1996; 88(7): 2375-84.
  • Abdul Hamid G. Target therapy and monitoring of chronic myeloid leukemia. World Journal of Pharmaceutical Research, 2015; 4(9): 391-405.
  • Verma D, Kantarjian HM, Jones D, et al. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood, 2009; 114(11): 2232-5.
  • Hamid GA, Akrabi A. Aberrant antigenexpression in patients with acute leukemia. ECClin Med Case Report, 2019; 53–60.
  • Gong Z, Zhou T, Liu H, et al. Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukaemia. Br J Haematol, 2020; 189(5): e207-11.
  • Cross NC, Melo JV, Feng L, Goldman JM. An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. Leukemia, 1994; 8(1): 186-9.
  • Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol, 2004; 5(1): 33-44.
  • Reckel S, Gehin C, Tardivon D, et al. Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase. Nat Commun., 2017; 8(1): 2101.
  • Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest, 2010; 120(7): 2254-64.
  • Steelman LS, Pohnert SC, Shelton JG, et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia, 2004; 18(2): 189-218.
  • Skorski T, Bellacosa A, Nieborowska-Skorska M, et al. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway. EMBO J., 1997; 16(20): 6151-61.
  • Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL. J Biol Chem., 1999; 274(16): 11060-7.
  • Kirchner D, Duyster J, Ottmann O, et al. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. Exp Hematol, 2003; 31(6): 504-11.
  • Hehlmann R. How I treat CML blast crisis. Blood, 2012; 120(4): 737-47.
  • Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood, 2011; 118(26): 6760-8.
  • Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood, 2016; 127(22): 2742-50.
  • Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood, 2018; 132(9): 948-61.
  • Bidikian A, Kantarjian H, Jabbour E, et al. Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J., 2022; 12(10).
  • Schonfeld L, Rinke J, Hinze A, et al. ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia, 2022; 36(9): 2242-9.
  • Ko TK, Javed A, Lee KL, et al. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia. Blood, 2020; 135(26): 2337-53.
  • Cortes JE, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood, 2012; 120(7): 1390-7.
  • Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program, 2019; 2019(1): 433-42.
  • Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013; 122(6): 872-84.
  • Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Bone marrow features and clinical findings in chronic myeloid leukemia—a comparative, multicenter, immunohistological and morphometric study on 614 patients. Leuk Lymphoma, 2000; 36(3-4): 295-308.
  • Senapati J, Sasaki K, Issa GC, et al. Management of chronic myeloid leukemia in 2023 - common ground and common sense. Blood Cancer J., 2023; 13(1): 58.
  • Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia, 2002; 16(1): 53-9.
  • Fabarius A, Kalmanti L, Dietz CT, et al. Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML. Ann Hematol, 2015; 94(12): 2015-24.
  • Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood, 2009; 114(24): 4939-43.
  • Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood, 2005; 105(6): 2281-6.
  • Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med., 2003; 349(15): 1423-32.
  • Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia, 2012; 26(10): 2172-5.
  • Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 2020; 34(4): 966-84.
  • Colafligi G, Scalzulli E, Porrazzo M, et al. Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome. Hematol Oncol, 2019; 37(5): 652-4.
  • Bernardi S, Malagola M, Zanaglio C, et al. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Med., 2019; 8(5): 2041-55.
  • Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia, 2020; 34(4): 966-84.
  • Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol, 2012; 30(3): 232-8.
  • Nazha A, Kantarjian H, Jain P, et al. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica, 2013; 98(11): 1686-8.
  • Hamid GA, Abdul-Rahman SA, Nasher S, HadiYA. Chronic Myeloid Leukemia in South Yemen.Int J Biopharm Sci., 2018; 1(2): 110.
  • Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med., 2017; 376(10): 917-27.
  • Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol, 2016; 34(20): 2333-40.
  • Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation, 2012; 125(17): 2128-37.
  • Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia, 2021; 35(2): 440-53.
  • Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd Trial. Leukemia, 2016; 30(5): 1044-54.
  • Brümmendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. Leukemia, 2022; 36(7): 1825-33.
  • Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol, 2018; 36(3): 231-7.
  • O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell., 2009; 16(5): 401-12.
  • Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood, 2018; 132(4): 393-404.
  • Jabbour E, Apperley J, Cortes J, et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia, 2024; 38(3): 475-81.
  • Schoepfer J, Jahnke W, Berellini G, et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem., 2018; 61(18): 8120-35.
  • Hochhaus A, Wang J, Kim D-W, et al. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med., 2024; 391(10): 885-98.
  • Hochhaus A, Rea D, Boquimpani C, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia, 2023; 37(3): 617-26.
  • Kantarjian H, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol, 2023; 10(10): e860-4.
  • Kantarjian H, Branford S, Breccia M, et al. Are there new relevant therapeutic endpoints in the modern era of the BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia, 2024; 38(5): 947-50.
  • Kantarjian HM, Welch MA, Jabbour E. Revisiting six established practices in the treatment of chronic myeloid leukaemia. Lancet Haematol, 2023; 10(10): e860-4.
  • Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia, 2016; 30(8): 1648-71.
  • Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia, 2020; 34(8): 2138-49.
  • Kantarjian H, Paul S, Thakkar J, Jabbour E. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA. Lancet Haematol, 2022; 9(11): e854-61.
  • Corbaux P, Madani ME, Tod M, et al. Is the optimal biological dose of oncologic molecular-targeted therapies also clinically effective? J Clin Oncol, 2019; 37(15_suppl): 3060.
  • Haddad FG, Kantarjian H. Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors. J Natl Compr Canc Netw, 2024; 22(1): e237116.
  • Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer, 2020; 126(1): 67-75.
  • Malagola M, Iurlo A, Buelli C, et al. The Italian Multicentric Randomized OPTKIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan. Clin Lymphoma Myeloma Leuk, 2024; 24(5): 323-31.
  • Breccia M, Olimpieri PP, Olimpieri O, et al. How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA). Cancer Med., 2020; 9(12): 4160-5.
  • Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res., 2014; 38(1): 10-20.
  • O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood, 2007; 110(7): 2242-9.
  • Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature, 2017; 543(7647): 733-7.
  • Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol, 2022; 15(1): 113.
  • Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell., 2014; 26(3): 428-42.
  • Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 2000; 96(3): 1070-9.
  • White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood, 2007; 110(12): 4064-72.
  • Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2008; 112(5): 2024-7.
  • Zhao H, Deininger MW. Declaration of Bcr-Abl1 independence. Leukemia, 2020; 34(11): 2827-36.
  • Soverini S, Bavaro L, De Benedittis C, et al. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood, 2020; 135(8): 534-41.
  • Soverini S, De Benedittis C, Mancini M, Martinelli G. Best practices in chronic myeloid leukemia monitoring and management. Oncologist, 2016; 21(5): 626-33.
  • Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood, 2009; 114(20): 4361-8.
  • Jabbour EJ, Sasaki K, Haddad FG, et al. The outcomes of patients with chronic myeloid leukemia treated with third-line BCR-ABL1 tyrosine kinase inhibitors. Am J Hematol, 2023; 98(4): 658-65.
  • Jiang Q, Li Z, Qin Y, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol, 2022; 15(1): 113.
  • Jiang Q, Li Z, Zhang G, et al. Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study. Blood, 2023; 142(Supplement 1): 869.
  • Jabbour E, Oehler VG, Koller PB, et al. Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. JAMA Oncol, 2025; 11(1): 28-35.
  • Jiang Q, Zhang Y, Wang Q, et al. Safety and Efficacy of Tgrx-678, a Potent BCR-ABL Allosteric Inhibitor in Patients with Tyrosine Kinase Inhibitor (TKI) Resistant/Refractory Chronic Myeloid Leukemia (CML): Preliminary Results of Phase I Study. Blood, 2023; 142(Supplement 1): 867.
  • Weiming L, Zhang Y, Zhu H, et al. Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML). Blood, 2024; 144: 480.
  • Saussele S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood, 2010; 115(10): 1880-5.
  • Haddad FG, Sasaki K, Bidikian A, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol, 2023; 98(10): 1619-26.
  • Barrett AJ, Ito S. The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century. Blood, 2015; 125(21): 3230-5.
  • Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol, 2010; 11(11): 1029-35.
  • Etienne G, Guilhot J, Rea D, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol, 2017; 35(3): 298-305.
  • Haddad FG, Sasaki K, Issa GC, et al. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. Am J Hematol, 2022; 97(7): 856-64.
  • Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol, 2018; 19(6): 747-57.
  • Farhat A, Kantarjian HM, Haddad FG, et al. Early Predictors of Treatment-Free Remission in Chronic Myeloid Leukemia. Blood, 2024; 144(Supplement 1): 6605.
  • Lee S, Mun Y-C, Kim H, et al. A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Blood, 2024; 144(Supplement 1): 1779.
  • Mahon F-X, Pfirrmann M, Dulucq S, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. Blood, 2020; 136(Supplement 1): 45-6.
  • Ilander M, Olsson-Stromberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia, 2017; 31(5): 1108-16.
  • Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol, 2014; 32(25): 2821-3.
  • Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol, 2020; 7(3): e218-25.
  • Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood, 2017; 129(7): 846-54.
  • Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma, 2020; 61(3): 650-9.
  • Ross DM, Masszi T, Gomez Casares MT, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol, 2018; 144(5): 945-54.
  • Massimo Breccia FC, Piciocchi A, Abruzzese E, et al. Sustenim Trial: Sustained Deep Molecular Response And Tfr Rate In The Long-Term Follow-Up. EHA Library, 2024; 422275.
  • Rea D, Ame S, Berger M, et al. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice. Haematologica, 2018; 103(5): 875-83.
  • Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol, 2014; 32(5): 424-30.
  • Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica, 2016; 101(6): 717-23.
  • Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood, 2013; 122(4): 515-22.
  • Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia, 2023; 37(1): 5-17.
  • Kantarjian HM, Tefferi A. Classification of accelerated phase chronic myeloid leukemia in the era of the BCR-ABL1 tyrosine kinase inhibitors: A work in progress. Am J Hematol, 2023; 98(9): 1350-3.
  • Berman E, Shah NP, Deninger M, et al. CML and the WHO: Why? J Clin Oncol, 2024; 42(9): 984-6.
  • Hornak T, Mayer J, Cicatkova P, et al. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors. Am J Hematol, 2024; 99(4): 763-6.
  • Senapati J, Ravandi F, DiNardo CD, et al. A Phase II Study of the Combination of Decitabine, Venetoclax and Ponatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Phase (MBP) or Philadelphia-Chromosome Positive (Ph+) Acute Myeloid Leukemia (AML). Blood, 2022; 140(Supplement 1): 3880-2.
  • Copland M, Slade D, McIlroy G, et al. Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. Lancet Haematol, 2022; 9(2): e121-32.
  • Karrar O, Jabbour E, Senapati J, et al. A Retrospective Analysis of Ponatinib-Based Therapy in Patients with Myeloid Blast Phase Chronic Myeloid Leukemia: Responses Rates, Outcomes and Patterns of Relapse. Blood, 2024; 144(Supplement 1): 3156.
  • Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia, 2013; 27(6): 1316-21.
  • Lipton JH, Chuah C, Guerci-Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol, 2016; 17(5): 612-21.
  • Latifi Y, Moccetti F, Wu M, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood, 2019; 133(14): 1597-606.
  • Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol, 2016; 34(20): 2333-40.
  • Savani S, Pawa A, Mahadevia H, Master SR. Cardiovascular complications associated with asciminib use: A retrospective analysis. J Clin Oncol, 2024; 42(16_suppl): Abstract 6563.
  • Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia, 2016; 30(8): 1648-71.
  • Lipton JH, Brümmendorf TH, Gambacorti-Passerini C, et al. Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev., 2022; 56: 100968.
  • Shah NP, Bhatia R, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2024; 22(1): 43-69.
  • Cortes J, Jabbour E, Kantarjian H, et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood, 2007; 110(12): 4005-11.
  • Lasica M, Willcox A, Burbury K, et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma, 2019; 60(7): 1796-802.
  • Russo D, Malagola M, Skert C, et al. Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer J., 2015; 5(9): e347.
  • Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood, 2016; 127(4): 392-9.
  • Weiming L, Danyu W, Jingming G, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia, 2020; 34: 1799-804.
  • Rea D, Mauro MJ, Cortes JE, et al. COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (icmlf) CML and COVID-19 (CANDID) Study. Blood, 2020; 136(Suppl 1): 46-7.
  • Kantarjian H, Jabbour E, Cortes J. Chronic Myeloid Leukemia. In: Loscalzo J, Fauci A, Kasper D, et al., eds. Harrison's Principles of Internal Medicine, 21e. McGraw-Hill Education, 2022.
  • Malhotra H, Radich J, Garcia-Gonzalez P. Meeting the needs of CML patients in resource-poor countries. Hematology Am Soc Hematol Educ Program, 2019; 2019(1): 433-42.
  • Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions? Mayo Clin Proc., 2015; 90(4): 500-4.
  • Rebecca Robbins RA. The Opaque Industry Secretly Inflating Prices for Prescription Drugs. New York Times. June 21, 2024.
  • Rooke-Ley H, Shah S, Brown ECF. Medicare Advantage and Consolidation's New Frontier - The Danger of UnitedHealthcare for All. N Engl J Med., 2024; 391(10): 885-98.
  • Hughes A, Clarson J, White DL, et al. Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation. Blood, 2016; 128(22): 1122.
  • Daver N, Benton CB, Ravandi F, et al. Phase I/II study of azacitidine (AZA) with venetoclax (VEN) for treatment of naïve higher risk myelodysplastic syndrome (MDS) and oligoblastic acute myeloid leukemia (AML). Blood, 2019; 134(Suppl 1): 568.
  • Nicolini FE, Dulucq S, Boureau L, et al. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Clin Cancer Res., 2019; 25(22): 6606-13.
  • Chen Y, Xu N, Yang Y, et al. Quality-of-life, mental health, and perspective on TKI dose reduction as a prelude to discontinuation in chronic phase chronic myeloid leukemia. Cancer Med., 2023; 12(16): 17239-52.